AONN+ Conference Abstracts
Evidence exists showing that enabling patients to engage in treatment decisions through education and shared decision-making is an effective tool in promoting self-efficacy, reducing barriers to care, and increasing the perceived benefits of self-involvement in one’s cancer diagnosis and treatment plan.
Julia Vandross, NP-BC, BSN, MSN, Stuart N. Atkinson, MB, ChB, Deborah M. Boldt-Houle, PhD, Tina DeNofrio, RN, BSN, OCN
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used drugs for the delivery of androgen deprivation therapy (ADT) in prostate cancer (PCa).
Maria Badillo, MSN, RN, Diana Nava, RN, Maria de la Rosa, Wendy Chen, PA, Maria Guerrero, DNP, MS, RN, Michael Wang, MD
Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor, approved for use in adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL), an aggressive B-cell malignancy.
Hairy cell leukemia (HCL) is a rare B-cell malignancy, diagnosed in ~1000 new patients a year in the US.
Jillian Settlemire, RN, Jocelyn E. Bushart, ANP-BC, Sandra Dai, PhD, MS, James P. Dean, MD, PhD, David Arthur, PhD, Paul Barr, MD, Steven Coutre, MD
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase (BTK), is approved in the US for the treatment of CLL/SLL and allows for treatment without chemotherapy.
Shelbi Burtt BSN, RN, OCN, Jessica Scott, RN, BSN, OCN, Cathy Zhou, MS, Lori Styles, MD, David Arthur, PhD, Bertrand Anz, MD, Ian W. Flinn, MD, PhD
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase, is approved in the US for CLL/SLL treatment, including in combination with obinutuzumab.
Twelve months of adjuvant oral dabrafenib + trametinib therapy significantly prolonged relapse-free survival versus placebo in patients with resected BRAF V600E/K–mutant stage III melanoma.
Individuals with hereditary breast and ovarian cancer syndrome (HBOC), caused by mutations in BRCA1 and BRCA2, have some of the highest cancer incidences of any known group.
Travel and global military presence dictate that international diseases can affect the American populace.
Simon Craddock Lee, PhD, MPH, Heidi A. Hamann, PhD, Magalis Z. Tijerina, BA, Cynthia Ortiz, MPH, Claudia Chavez, MBA, Noel Santini, MD, David E. Gerber, MD
While adherence to annual screening exceeded 90% in the National Lung Screening Trial, the trial population was disproportionately white, educated, and received care in the tightly controlled environment of a clinical trial.